These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 33718258)
1. Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis. Shrivastav MT; Malik Z; Somlata Front Cell Infect Microbiol; 2020; 10():628257. PubMed ID: 33718258 [TBL] [Abstract][Full Text] [Related]
2. Target identification and intervention strategies against amebiasis. Nagaraja S; Ankri S Drug Resist Updat; 2019 May; 44():1-14. PubMed ID: 31112766 [TBL] [Abstract][Full Text] [Related]
3. Review of zoonotic amebiasis: Epidemiology, clinical signs, diagnosis, treatment, prevention and control. Li J; Cui Z; Li X; Zhang L Res Vet Sci; 2021 May; 136():174-181. PubMed ID: 33676155 [TBL] [Abstract][Full Text] [Related]
4. Bioactivity of Farnesyltransferase Inhibitors Against Probst A; Nguyen TN; El-Sakkary N; Skinner D; Suzuki BM; Buckner FS; Gelb MH; Caffrey CR; Debnath A Front Cell Infect Microbiol; 2019; 9():180. PubMed ID: 31192168 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Antiamebic Compounds That Inhibit Cysteine Synthase From the Enteric Parasitic Protist Mori M; Tsuge S; Fukasawa W; Jeelani G; Nakada-Tsukui K; Nonaka K; Matsumoto A; Ōmura S; Nozaki T; Shiomi K Front Cell Infect Microbiol; 2018; 8():409. PubMed ID: 30568921 [TBL] [Abstract][Full Text] [Related]
6. [Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine]. Chacín-Bonilla L Invest Clin; 2012 Sep; 53(3):301-14. PubMed ID: 23248973 [TBL] [Abstract][Full Text] [Related]
7. High-Throughput Screening of Ehrenkaufer GM; Suresh S; Solow-Cordero D; Singh U Front Cell Infect Microbiol; 2018; 8():276. PubMed ID: 30175074 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of paromomycin for treating amebiasis in Japan. Kikuchi T; Koga M; Shimizu S; Miura T; Maruyama H; Kimura M Parasitol Int; 2013 Dec; 62(6):497-501. PubMed ID: 23850836 [TBL] [Abstract][Full Text] [Related]
9. Characterization of Entamoeba fatty acid elongases; validation as targets and provision of promising leads for new drugs against amebiasis. Mi-Ichi F; Tsugawa H; Vo TK; Kurizaki Y; Yoshida H; Arita M PLoS Pathog; 2024 Aug; 20(8):e1012435. PubMed ID: 39172749 [TBL] [Abstract][Full Text] [Related]
10. Glycerol biosynthetic pathway plays an essential role in proliferation and antioxidative defense in the human enteric protozoan parasite Entamoeba histolytica. Jeelani G; Balogun EO; Husain A; Nozaki T Sci Rep; 2023 Sep; 13(1):14596. PubMed ID: 37669981 [TBL] [Abstract][Full Text] [Related]
12. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. Carrero JC; Reyes-López M; Serrano-Luna J; Shibayama M; Unzueta J; León-Sicairos N; de la Garza M Int J Med Microbiol; 2020 Jan; 310(1):151358. PubMed ID: 31587966 [TBL] [Abstract][Full Text] [Related]
13. Flavonoids as a Natural Treatment Against Martínez-Castillo M; Pacheco-Yepez J; Flores-Huerta N; Guzmán-Téllez P; Jarillo-Luna RA; Cárdenas-Jaramillo LM; Campos-Rodríguez R; Shibayama M Front Cell Infect Microbiol; 2018; 8():209. PubMed ID: 29988403 [TBL] [Abstract][Full Text] [Related]
14. [The current view of the diagnosis and management of amebiasis in the light of the authors own case reports]. Voldřich M; Novotný P; Tyll T; Rudiš J; Belšan T; Hedlová D; Stefanová M Epidemiol Mikrobiol Imunol; 2014 Sep; 63(3):226-31. PubMed ID: 25412488 [TBL] [Abstract][Full Text] [Related]
15. Editorial: Recent Progresses in Amebiasis. Debnath A; Rodriguez MA; Ankri S Front Cell Infect Microbiol; 2019; 9():247. PubMed ID: 31338336 [No Abstract] [Full Text] [Related]
16. Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica. Kangussu-Marcolino MM; Singh U Antimicrob Agents Chemother; 2022 Feb; 66(2):e0120721. PubMed ID: 34871094 [TBL] [Abstract][Full Text] [Related]